News of the approval of the new Alzheimer’s drug has hit the headlines this week. Lecanemab has been approved by the MHRA, the UK’s regulator, but has been rejected by NICE so it will not be available on the NHS. Lecanemab is part of a new class of drugs that is emerging. It slows the […]

News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]